Molecular-genetic approach to predicting the effectiveness of aggressive non-Нodgkin's lymphomas therapy
Purpose: to study the effectiveness of therapy of patients with aggressive non-Hodgkin's lymphoma receiving immunochemotherapy, depending on the genotype of rs1625895. The survey group consists of 41 patients with high grade B-cell non-Hodgkin's lymphomas diagnosed in the Novosibirsk City Hematology Center from 2004 to 2007. All patients underwent the therapy with the rituximab. In the general group of patients remission was obtained in 59 % of cases, 5-year overall survival rate was 36.6 %, disease-free - 24.4 %. In the subgroup of patients with the genotype G/G rs1625895 remission was obtained in 42.9 % of people. It was statistically significant (p = 0.003) lower than in the subgroup of patients with the genotype G/A and A/A - 92.3 %. The statistically significant association of genotype G/G with deterioration in the overall (21.4 %) and disease-free survival (10.7 %) vs. 69.2 % (p = 0.004) and 53.9 % (p = 0.0006) with genotype G/A and A/A respectively has been shown.
About Authors (Correspondence):
Voropaeva E.N. - candidate of medical sciences, researcher of the laboratory of molecular-genetic study methods of the therapeutic diseases, е-mail: firstname.lastname@example.org
Voevoda M.I. - corresponding member of the RAMS, doctor of medical sciences, professor, director
Pospelova T.I. - doctor of medical sciences, professor, head of the chair for therapy, hematology and transfusiology, е-mail: email@example.com
Beresina O.V. - candidate of medical sciences, assistant professor of the chair for therapy, hematology and transfusiology, е-mail: firstname.lastname@example.org
Maksimov V.N. - doctor of medical sciences, professor, head of the laboratory of molecular-genetic study methods of the therapeutic diseases, е-mail: email@example.com